Skip to content

Supernus Pharmaceuticals SUPN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
658K+4,600%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, exercises in period?
Supernus Pharmaceuticals (SUPN) reported share-based compensation arrangement by share-based payment award, options, exercises in period of 443.4K in Q1 2026.
What does share-based compensation arrangement by share-based payment award, options, exercises in period mean?
The number of common shares issued as a result of employees exercising their vested stock options. This activity directly impacts the total weighted-average shares outstanding and reflects the conversion of incentive compensation into equity ownership.